Additional Info on the Mosaic Transaction with Vivint
by Kristi Marvin on 2019-09-16 at 1:27pm

Mosaic Acquisition Corp. (MOSC), filed their 8-k mid-morning so we have some additional information regarding their transaction with Vivint.

  • First up, while Mosaic will need to extend three months post their 24 month deadline of October 23rd, this SPAC has the ability to extend to 27 months without an extension vote.  Per the prospectus:  “…. 24 months from the closing of this offering, or 27 months from the closing of this offering if we have executed a letter of intent, agreement in principle or definitive agreement for an initial business combination within 24 months from the closing of this offering….
  • Two, Mosaic also has the ability to call their warrants for shares at $10.00. This is in addition to Mosaic’s ability to call their warrants for cash or cashless exercise at $18.00.  That’s not to say they will automatically opt for the call for shares (they may prefer the cash), but it’s something to consider if you’re a warrant holder.
  • Three, termination rights:  If the merger agreement is terminated, due to either a superior proposal or if Vivint’s Board of Directors change their recommendation, Mosaic is entitled to receive a termination fee of $81,060,000.
  • Four, notable conditions to termination: this transaction can be terminated by either Mosaic or Vivint Smart Home if the transactions are not consummated on or before January 22, 2020 (or April 23, 2020, if stockholders of Common Stock have approved an extended deadline to consummate the Business Combination)
  • Five, Vivint’s notable conditions to closing: redemptions must be less than 10,350,000 shares in the aggregate.  As a reminder, Mosaic has 34,500,000 public shares outstanding, so the 10.35 million figure represents fewer than 30%.

The fact that Mosaic does not need to go to an extension vote to extend is significant.  This SPAC does not need to worry about their cash in trust being depleted in order to extend and potentially having to re-jigger any parts of this deal. HOWEVER, at the combination closing vote, the minimum amount of redemptions of 10.35 million shares means 70% of the Trust must NOT redeem.  Which means the Mosaic and Vivint teams have their work cut out for them as far as marketing. Keeping 70% in trust can be a challenging hurdle if a combination is not a very well received.  Let’s see what happens when they hit the road and get to tell their story.

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved